Debra G B Leonard

Summary

Affiliation: University of Pennsylvania
Country: USA

Publications

  1. ncbi Medical practice and gene patents: a personal perspective
    Debra G B Leonard
    Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Acad Med 77:1388-91. 2002
  2. ncbi Diagnostic testing fails the test
    Jon F Merz
    Center for Bioethics, University of Pennsylvania, Philadelphia, Pennsylvania 19104-3308, USA
    Nature 415:577-9. 2002
  3. ncbi Changes in food reward following smoking cessation: a pharmacogenetic investigation
    Caryn Lerman
    Department of Psychiatry, Abramson Cancer Center, University of Pennsylvania, 3535 Market Street, Suite 4100, Philadelphia, PA 19104, USA
    Psychopharmacology (Berl) 174:571-7. 2004
  4. ncbi Association of susceptibility alleles in ELAC2/HPC2, RNASEL/HPC1, and MSR1 with prostate cancer severity in European American and African American men
    Hanna Rennert
    Department of Pathology and Laboratory Medicine, University of Pennsylvania, Health System, 7 Gates West, 3400 Spruce Street, Philadelphia, PA 19104, USA
    Cancer Epidemiol Biomarkers Prev 14:949-57. 2005
  5. ncbi Spinal muscular atrophy genetic testing experience at an academic medical center
    Shuji Ogino
    Department of Pathology and Laboratory Medicine, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania 19104, USA
    J Mol Diagn 4:53-8. 2002
  6. ncbi Genetic risk assessment in carrier testing for spinal muscular atrophy
    Shuji Ogino
    Molecular Pathology Laboratory, Department of Pathology and Laboratory Medicine, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, USA
    Am J Med Genet 110:301-7. 2002
  7. ncbi Effects of patents and licenses on the provision of clinical genetic testing services
    Mildred K Cho
    Center for Biomedical Ethics, Stanford University, Palo Alto, California, USA
    J Mol Diagn 5:3-8. 2003
  8. ncbi Inverse correlation between SMN1 and SMN2 copy numbers: evidence for gene conversion from SMN2 to SMN1
    Shuji Ogino
    Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Eur J Hum Genet 11:275-7. 2003
  9. ncbi Multiplex RT-PCR for the detection of leukemia-associated translocations: validation and application to routine molecular diagnostic practice
    Manuel Salto-Tellez
    Department of Pathology, National University of Singapore, Singapore
    J Mol Diagn 5:231-6. 2003

Detail Information

Publications9

  1. ncbi Medical practice and gene patents: a personal perspective
    Debra G B Leonard
    Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Acad Med 77:1388-91. 2002
  2. ncbi Diagnostic testing fails the test
    Jon F Merz
    Center for Bioethics, University of Pennsylvania, Philadelphia, Pennsylvania 19104-3308, USA
    Nature 415:577-9. 2002
  3. ncbi Changes in food reward following smoking cessation: a pharmacogenetic investigation
    Caryn Lerman
    Department of Psychiatry, Abramson Cancer Center, University of Pennsylvania, 3535 Market Street, Suite 4100, Philadelphia, PA 19104, USA
    Psychopharmacology (Berl) 174:571-7. 2004
    ..Despite the high prevalence and public health significance of weight gain following smoking cessation, little is known about the underlying bio-behavioral mechanisms or effective therapies...
  4. ncbi Association of susceptibility alleles in ELAC2/HPC2, RNASEL/HPC1, and MSR1 with prostate cancer severity in European American and African American men
    Hanna Rennert
    Department of Pathology and Laboratory Medicine, University of Pennsylvania, Health System, 7 Gates West, 3400 Spruce Street, Philadelphia, PA 19104, USA
    Cancer Epidemiol Biomarkers Prev 14:949-57. 2005
    ..Therefore, MSR1 and RNASEL may play a role in prostate cancer progression and severity...
  5. ncbi Spinal muscular atrophy genetic testing experience at an academic medical center
    Shuji Ogino
    Department of Pathology and Laboratory Medicine, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania 19104, USA
    J Mol Diagn 4:53-8. 2002
    ..We conclude that comprehensive SMA testing, including SMN1 deletion analysis, SMN1 gene dosage analysis, and linkage analysis, offers the most complete evaluation of SMA patients and their families...
  6. ncbi Genetic risk assessment in carrier testing for spinal muscular atrophy
    Shuji Ogino
    Molecular Pathology Laboratory, Department of Pathology and Laboratory Medicine, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, USA
    Am J Med Genet 110:301-7. 2002
    ..We present updated calculations for disease and non-disease allele frequencies and we describe how these frequencies can be used for genetic risk assessment in carrier testing for SMA...
  7. ncbi Effects of patents and licenses on the provision of clinical genetic testing services
    Mildred K Cho
    Center for Biomedical Ethics, Stanford University, Palo Alto, California, USA
    J Mol Diagn 5:3-8. 2003
    ..Furthermore, our findings suggest that clinical geneticists feel that their research is inhibited by patents. The effects of patents and licenses on patients' access to tests, and the costs and quality thereof, remains to be determined...
  8. ncbi Inverse correlation between SMN1 and SMN2 copy numbers: evidence for gene conversion from SMN2 to SMN1
    Shuji Ogino
    Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Eur J Hum Genet 11:275-7. 2003
    ..In conclusion, our data provide evidence that gene conversion from SMN2 to SMN1 occurs, and that SMN1 converted from SMN2 is present in the general population...
  9. ncbi Multiplex RT-PCR for the detection of leukemia-associated translocations: validation and application to routine molecular diagnostic practice
    Manuel Salto-Tellez
    Department of Pathology, National University of Singapore, Singapore
    J Mol Diagn 5:231-6. 2003
    ..This study illustrates the utility of a kit-based multiplex RT-PCR assay for the molecular diagnosis and monitoring of leukemias and reinforces the complementary roles of molecular testing and cytogenetics in diagnostic hematopathology...